Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

ClinicalTrials.gov ID: NCT02104388

Public ClinicalTrials.gov record NCT02104388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders

Study identification

NCT ID
NCT02104388
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Enrollment
69 participants

Conditions and interventions

Interventions

  • SJP-0035 Ophthalmic Solution Drug
  • Vehicle of SJP-0035 Ophthalmic Solution Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 7, 2014
Primary completion
Aug 3, 2015
Completion
Aug 3, 2015
Last update posted
Mar 28, 2021

2014 – 2015

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
Senju Investigational Site Little Rock Arkansas 72205
Senju Investigational Site Glendale California 91206
Senju Investigational Site Glendora California 91741
Senju Investigational Site Huntington Beach California 92647
Senju Investigational Site Lancaster California 93534
Senju Investigational Site Newport Beach California 92663
Senju Investigational Site Pasadena California 91107
Senju Investigational Site Petaluma California 94954
Senju Investigational Site Santa Maria California 93454
Senju Investigational Site Hoffman Estates Illinois 60169
Senju Investigational site Edgewood Kentucky 41017
Senju Investigational Site Kansas City Missouri 64111
Senju Investigational Site Palisades Park New Jersey 07650
Senju Investiational Site Rochester New York 14642
Senju Investigational Site High Point North Carolina 27262
Senju Investigational Site Rapid City South Dakota 57701
Senju Investigational Site Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02104388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 28, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02104388 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →